Opinion|Videos|July 31, 2024
Will Neo-Adjuvant Therapies Replace Surgery plus Adjuvant Treatment for Resectable NSCLC?
Jyoti D. Patel, MD, and Rajat Thawani, MBBS, tackle the question of whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable non–small cell lung cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Findings from the phase 1 KANDLELIT-001 study support further investigation of calderasib plus pembrolizumab in KRAS G12C-mutated metastatic NSCLC.
Initial data from the ROSETTA Lung-107 trial support further study of pumitamig in metastatic NSCLC previously managed with an immunotherapy-based regimen.
Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population.
Data from the phase 3 Krascendo 1 trial support divarasib as a new standard in previously treated KRAS G12C–mutated non–small cell lung cancer.
Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.
Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.
At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.
The therapeutic cancer vaccine OSE2101 combined with either docetaxel or nivolumab met the primary end point of 1-year overall survival in the Combi-TED trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Ivonescimab Combo Improves Survival in Advanced Biliary Tract Cancer
2
Osimertinib/Savolitinib Improves Survival in MET-Altered EGFR-Mutant NSCLC
3
FDA Approves Talazoparib/Enzalutamide for HRR Gene-Altered Metastatic Prostate Cancer
4
How Can Functional Modeling, AI Accelerate Translational Breast Cancer Research?
5